SPK 002
Alternative Names: SPK-002Latest Information Update: 27 May 2024
At a glance
- Originator Institut Pasteur
- Developer SpikImm
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 07 Dec 2022 SpikImm plans Emergency Use Authorization for SPK 002 in COVID-2019 infections (Prevention) in 2023
- 07 Dec 2022 SpikImm plans a phase II trial in COVID-2019 infections (Prevention) in 2Q of 2023
- 20 Oct 2022 Preclinical trials in COVID-2019 infections (Prevention) in France (Parenteral) prior to October 2022